This review explores antibody-drug conjugates and immune checkpoint inhibitors in metastatic urothelial carcinoma, highlighting their potential for personalized treatment.
Key Points
Antibody-drug conjugates demonstrate promising efficacy in metastatic urothelial carcinoma management.
Transformative therapies like enfortumab vedotin and sacituzumab govitecan improve treatment options for patients.